trending Market Intelligence /marketintelligence/en/news-insights/trending/adlkpnvyhyrtmtlopaepha2 content esgSubNav
In This List

CASI Pharmaceuticals raises $50M via sale of shares

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


CASI Pharmaceuticals raises $50M via sale of shares

CASI Pharmaceuticals Inc. raised $50 million to prepare for the commercialization of its first product in China.

Rockville, Md.-based CASI Pharmaceuticals sold 15,432,091 shares of the company at $3.24 each, complete with warrants to purchase up to an additional 6,172,832 stock at $3.69 apiece.

ETP Global Fund LP; IDG-Accel China Growth Fund III; and Robert Duggan, former CEO and chairman of Pharmacyclics Inc., led the funding.

The company's Evomela, Marqibo and Zevalin products are in various regulatory stages for market approval in China.